Clinical Takeaway Archives - Page 18 of 20

T2D and the heart

In this era of SGLT2 inhibitors and GLP1 agonists, we need to initiate these therapies early because of their cardioprotective and renoprotective (for SGLT2I) benefits

T2D and the foot

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

Epigenetic testing

The reality of epigenetic tests in general practice may not be that far away

What’s in and what’s out in T2D management guidelines

The evidence for the use of SGLT2 inhibitors and GLP-1a is increasing and practical tips for GPs to help us in managing patients with T2DM

Free ‘staff’ for professionals treating suicidal patients

When someone is suicidal, those who are close to the distressed person do not know what to do and often feel paralysed - because they are not sure what is the right thing to say

Oral prednisone, asthma and osteoporosis risk

If needed, oral prednisone should still be used but do so judiciously and keep in mind that the risk of osteoporosis is directly linked to cumulative lifetime doses of oral steroid

A practical approach to first, second and third line treatment

In the patient with newly diagnosed T2DM without micro or macrovascular complications, achieving good glycaemic control is important and this together with an eye to avoiding weight gain and hypoglycaemia will drive your choice of a second-line agent

Chronic vestibular syndromes – Part 3

Recurrent vertigo, recurrent spontaneous vertigo, imbalance ataxia and persistent postural perceptual dizziness (PPPD)

T2D and the kidney

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

Non-insulin injectables for T2D

GLP1 agonists are a very important management option - GPs who have not yet used this class of medications should learn more and start

Acute vestibular syndromes – Part 2

Acute vestibular and acute transient vestibular syndromes and confirming the diagnosis of vestibular neuritis

Getting your patients into a clinical trial

Here's an opportunity for GP practices to reach out to patients so they can be involved in medical research

Clinical Takeaway

T2D and the heart

In this era of SGLT2 inhibitors and GLP1 agonists, we need to initiate these therapies early because of their cardioprotective and renoprotective (for SGLT2I) benefits

T2D and the foot

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

Epigenetic testing

The reality of epigenetic tests in general practice may not be that far away

What’s in and what’s out in T2D management guidelines

The evidence for the use of SGLT2 inhibitors and GLP-1a is increasing and practical tips for GPs to help us in managing patients with T2DM

Free ‘staff’ for professionals treating suicidal patients

When someone is suicidal, those who are close to the distressed person do not know what to do and often feel paralysed - because they are not sure what is the right thing to say

Oral prednisone, asthma and osteoporosis risk

If needed, oral prednisone should still be used but do so judiciously and keep in mind that the risk of osteoporosis is directly linked to cumulative lifetime doses of oral steroid

A practical approach to first, second and third line treatment

In the patient with newly diagnosed T2DM without micro or macrovascular complications, achieving good glycaemic control is important and this together with an eye to avoiding weight gain and hypoglycaemia will drive your choice of a second-line agent

Chronic vestibular syndromes – Part 3

Recurrent vertigo, recurrent spontaneous vertigo, imbalance ataxia and persistent postural perceptual dizziness (PPPD)

T2D and the kidney

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

Non-insulin injectables for T2D

GLP1 agonists are a very important management option - GPs who have not yet used this class of medications should learn more and start

Acute vestibular syndromes – Part 2

Acute vestibular and acute transient vestibular syndromes and confirming the diagnosis of vestibular neuritis

Getting your patients into a clinical trial

Here's an opportunity for GP practices to reach out to patients so they can be involved in medical research

Get the app

Site

Company

Connect

Legal

Healthed

Clinical Takeaway

In this era of SGLT2 inhibitors and GLP1 agonists, we need to initiate these therapies early because of their cardioprotective and renoprotective (for SGLT2I) benefits

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

The reality of epigenetic tests in general practice may not be that far away

The evidence for the use of SGLT2 inhibitors and GLP-1a is increasing and practical tips for GPs to help us in managing patients with T2DM

When someone is suicidal, those who are close to the distressed person do not know what to do and often feel paralysed - because they are not sure what is the right thing to say

If needed, oral prednisone should still be used but do so judiciously and keep in mind that the risk of osteoporosis is directly linked to cumulative lifetime doses of oral steroid

In the patient with newly diagnosed T2DM without micro or macrovascular complications, achieving good glycaemic control is important and this together with an eye to avoiding weight gain and hypoglycaemia will drive your choice of a second-line agent

Recurrent vertigo, recurrent spontaneous vertigo, imbalance ataxia and persistent postural perceptual dizziness (PPPD)

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

GLP1 agonists are a very important management option - GPs who have not yet used this class of medications should learn more and start

Acute vestibular and acute transient vestibular syndromes and confirming the diagnosis of vestibular neuritis

Here's an opportunity for GP practices to reach out to patients so they can be involved in medical research

Get the app

Site

Company

Connect

Legal

Already a member? Log in for full access

Don't have an existing account? Sign up today

Extra Details

Healthed